L0909

L0909 is a potent and selective orally available HCV entry inhibitor (EC50 = 0.022 μM, SI > 600) with a novel mechanism. It demonstrates activity against clinically resistant mutants and exhibits synergistic potential with existing therapies, making it a promising candidate for single or combination antiviral research in vitro.